Back to Search
Start Over
Preoperative Assessment of Pancreatic Cancer with FDG PET/MR Imaging versus FDG PET/CT Plus Contrast-enhanced Multidetector CT: A Prospective Preliminary Study.
- Source :
-
Radiology [Radiology] 2017 Jan; Vol. 282 (1), pp. 149-159. Date of Electronic Publication: 2016 Aug 24. - Publication Year :
- 2017
-
Abstract
- Purpose To determine the diagnostic performance of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance (MR) imaging in the preoperative assessment of pancreatic cancer in comparison with that of FDG PET/computed tomography (CT) plus contrast material-enhanced multidetector CT. Materials and Methods This prospective study was approved by the institutional review board; written informed consent was obtained. Thirty-seven patients with 39 pancreatic tumors underwent preoperative FDG PET/MR imaging, PET/CT, and contrast-enhanced multidetector CT. The authors measured maximal and mean standardized uptake values (SUV <subscript>max</subscript> and SUV <subscript>mean</subscript> , respectively) of pancreatic cancer at PET/MR imaging and PET/CT. Two radiologists independently reviewed the two imaging sets (set 1, PET/MR imaging; set 2, PET/CT plus multidetector CT) to determine tumor resectability according to a five-point scale, N stage (N0 or N positive), and M stage (M0 or M1). With use of clinical-surgical-pathologic findings as the standard of reference (n = 20), diagnostic performances of the two imaging sets were compared by using the McNemar test. Results Both SUV <subscript>max</subscript> and SUV <subscript>mean</subscript> of pancreatic tumors showed strong correlations between PET/MR imaging and PET/CT (r = 0.897 and 0.890, respectively; P < .001). The diagnostic performance of PET/MR imaging was not significantly different from that of PET/CT plus multidetector CT in the assessment of tumor resectability (area under the receiver operating characteristic curve: 0.891 vs 0.776, respectively, for reviewer 1 [P = .109] and 0.859 vs 0.797 for reviewer 2 [P = .561]), N stage (accuracy: 54% [seven of 13 patients] vs 31% [four of 13 patients]; P = .250 for both reviewers), and M stage (accuracy: 94% [16 of 17 patients] vs 88% [15 of 17 patients] for reviewer 1 [P > .999] and 94% [16 of 17 patients] vs 82% [14 of 17 patients] for reviewer 2 [P = .500]). Conclusion FDG PET/MR imaging showed a diagnostic performance similar to that of PET/CT plus contrast-enhanced multidetector CT in the preoperative evaluation of the resectability and staging of pancreatic tumors. <superscript>©</superscript> RSNA, 2016 Online supplemental material is available for this article.
- Subjects :
- Contrast Media
Female
Fluorodeoxyglucose F18
Humans
Male
Middle Aged
Neoplasm Staging
Pancreatic Neoplasms pathology
Pancreatic Neoplasms surgery
Preoperative Period
Prospective Studies
Radiopharmaceuticals
Magnetic Resonance Imaging
Pancreatic Neoplasms diagnostic imaging
Positron Emission Tomography Computed Tomography
Subjects
Details
- Language :
- English
- ISSN :
- 1527-1315
- Volume :
- 282
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Radiology
- Publication Type :
- Academic Journal
- Accession number :
- 27556273
- Full Text :
- https://doi.org/10.1148/radiol.2016152798